SCHEMBL4591323

SCHEMBL4591323

Cc1nc2n(c1C)CCCC2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.39
HTR2A P28223 3/20 0.39
HTR1A P08908 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 6/20 0.34
KDM4E B2RXH2 5/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
CYP1A2 P05177 2/20 0.34
HSD17B10 Q99714 2/20 0.34
USP2 O75604 1/20 0.34
BCHE P06276 1/20 0.34
CFTR P13569 1/20 0.34
ALOX15 P16050 1/20 0.34
ACHE P22303 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
GOPC Q9HD26 1/20 0.34
POLB P06746 1/20 0.34
APEX1 P27695 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222472 0.78 DRD2 (0.34) DRD2HTR2AHTR1ASMN1; SMN2ALDH1A1
SCHEMBL13525311 0.77 DRD2 (0.51) DRD2HTR2AHTR1AKDM4ECYP1A2
SCHEMBL14278538 0.72 ATM (0.46) SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1
SCHEMBL7979271 0.72 L3MBTL1 (0.41) DRD2HTR2AHTR1ASMN1; SMN2ALDH1A1
SCHEMBL4580083 0.68 SMN1; SMN2 (0.32) SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1
SCHEMBL13360488 0.67 POLB (0.48) SMN1; SMN2ALDH1A1HSD17B10ALOX15POLB
SCHEMBL2616364 0.67 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1
SCHEMBL8810859 0.66 GRM2 (0.49) SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1
SCHEMBL19006734 0.65 POLB (0.52) SMN1; SMN2ALDH1A1HSD17B10ALOX15POLB
SCHEMBL5619238 0.63 L3MBTL1 (0.37) SMN1; SMN2ALDH1A1KDM4EL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899341-A1 SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS Nycomed GmbH (DE) 2008-03-19 EP disclosed
US-7314935-B2 Tricyclic n-acyl compounds ALTANA PHARMA AG (DE) 2008-01-01 US disclosed
EP-1286999-B1 PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS NYCOMED GMBH (DE) 2007-12-19 EP disclosed
US-7189736-B2 Prodrugs of imidazopyridine derivatives ALTANA PHARMA AG (DE) 2007-03-13 US disclosed
EP-1303519-B1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2007-03-07 EP disclosed
WO-2006134112-A1 SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS NYCOMED GMBH (DE) 2006-12-21 WO disclosed
US-7141567-B2 Polysubstituted imidazopyridines as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2006-11-28 US disclosed
US-20060194972-A1 Process for the production of imidazopyridin-8-ones ALTANA PHARMA AG (DE) 2006-08-31 US disclosed
EP-1414821-B1 TRICYCLIC EPOXIDES ALTANA PHARMA AG (DE) 2006-08-16 EP disclosed
EP-1313739-B1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2006-07-05 EP disclosed
EP-1303519-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA Pharma AG (DE) 2003-04-23 EP disclosed
WO-2001072748-A9 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2003-04-10 WO disclosed
EP-1286993-A1 IMIDAZOPYRIDIN-8-ONES ALTANA Pharma AG (DE) 2003-03-05 EP disclosed
EP-1286999-A1 PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS ALTANA Pharma AG (DE) 2003-03-05 EP disclosed
WO-2003014119-A1 TRICYCLIC EPOXIDES ALTANA PHARMA AG (DE) 2003-02-20 WO disclosed
WO-2001072757-A1 TRICYCLIC IMIDAZOPYRIDINES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072755-A1 PYRANO[2,3-C]IMIDAZO[-1,2-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072756-A1 PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072748-A1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072754-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194972-A1 Process for the production of imidazopyridin-8-ones NISCH, NDUFS8, BRSK1 DRD2 4136/4885HTR2A 2608/4885HTR1A 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.